Skip to main content


  • Research article
  • Open Access

Comparative genomics allowed the identification of drug targets against human fungal pathogens

  • 1, 3,
  • 1,
  • 1,
  • 2,
  • 3 and
  • 1Email author
BMC Genomics201112:75

  • Received: 26 August 2010
  • Accepted: 27 January 2011
  • Published:



The prevalence of invasive fungal infections (IFIs) has increased steadily worldwide in the last few decades. Particularly, there has been a global rise in the number of infections among immunosuppressed people. These patients present severe clinical forms of the infections, which are commonly fatal, and they are more susceptible to opportunistic fungal infections than non-immunocompromised people. IFIs have historically been associated with high morbidity and mortality, partly because of the limitations of available antifungal therapies, including side effects, toxicities, drug interactions and antifungal resistance. Thus, the search for alternative therapies and/or the development of more specific drugs is a challenge that needs to be met. Genomics has created new ways of examining genes, which open new strategies for drug development and control of human diseases.


In silico analyses and manual mining selected initially 57 potential drug targets, based on 55 genes experimentally confirmed as essential for Candida albicans or Aspergillus fumigatus and other 2 genes (kre2 and erg6) relevant for fungal survival within the host. Orthologs for those 57 potential targets were also identified in eight human fungal pathogens (C. albicans, A. fumigatus, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Paracoccidioides lutzii, Coccidioides immitis, Cryptococcus neoformans and Histoplasma capsulatum). Of those, 10 genes were present in all pathogenic fungi analyzed and absent in the human genome. We focused on four candidates: trr1 that encodes for thioredoxin reductase, rim8 that encodes for a protein involved in the proteolytic activation of a transcriptional factor in response to alkaline pH, kre2 that encodes for α-1,2-mannosyltransferase and erg6 that encodes for Δ(24)-sterol C-methyltransferase.


Our data show that the comparative genomics analysis of eight fungal pathogens enabled the identification of four new potential drug targets. The preferred profile for fungal targets includes proteins conserved among fungi, but absent in the human genome. These characteristics potentially minimize toxic side effects exerted by pharmacological inhibition of the cellular targets. From this first step of post-genomic analysis, we obtained information relevant to future new drug development.


  • Homology Modeling
  • Posaconazole
  • Micafungin
  • Anidulafungin
  • Potential Drug Target


The frequency and diversity of invasive fungal infections have changed over the last 25 years. The emergence of less common, but medically important, fungi has increased, especially in the large populations of immunocompromised patients and of those hospitalized with serious underlying diseases [1, 2]. These patients develop more severe clinical forms of mycoses, which are commonly fatal, and they are more susceptible to infections by opportunistic fungi than non-immunocompromised people [3]. The antifungal agents currently available for the treatment of systemic mycoses include four groups of drugs: polyenes (amphotericin B), azoles (fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole), echinocandins (caspofungin, anidulafungin, and micafungin) and flucytosines [4]. Conventional amphotericin B, despite being a broad-spectrum fungicidal agent with little intrinsic or acquired resistance, is limited by its serious toxicities and lack of an oral formulation for systemic therapy. In recent years, three lipid formulations of amphotericin B (amphotericin B lipid complex, amphotericin B cholesteryl sulfate and liposomal amphotericin B) have been developed and approved by the Food and Drug Administration (FDA). Although less nephrotoxic than deoxycholate amphotericin B, lipid amphotericin B nephrotoxicity still limits treatment compared to the newer triazoles and echinocandins [5]. The triazoles are the most widely used antifungal agents and have activity against many fungal pathogens, with less serious nephrotoxic effects observed than with amphotericin B. However, the azoles antifungals have many drug-drug interactions with multiple drug classes owing to their interference with hepatic cytochrome P-450 enzymes [6]. Another problem with azoles therapy is the acquired resistance of many pathogens to these drugs, which is the most common cause of refractory infection. Thus, the search for alternative therapies and/or the development of more specific drugs is a challenge. Recently, efforts have been devoted to the chemistry side of discovering new antifungal agents, including the development of third-generation azoles or a new therapeutic class of antifungal drugs, such as echinocandins [7]. Additionally, nanotechnology approaches have improved the development of innovative products that reduce side effects by lowering dose administration of already available drugs, such as amphotericin B nanoencapsulated [810]. Many advances have been made in antifungal drug development in the past decade. However, the search for more specific drugs, in an effort to overcome the global problem of resistance to antifungal agents and minimize the serious side effects, is increasingly relevant and necessary.

Currently, drug research and development are expensive and time consuming. An estimated 14 years and an average of $1.8 billion is the investment required to develop a new drug that will reach the market [11]. Selecting new molecular targets by comparative genomics, homology modeling and virtual screening of compounds is promising in the process of new drug discovery. In fact, technological advances over the past two decades have led to the accumulation of genome-wide sequence data for many different fungal species. As the number of sequenced genomes rapidly increases, searching and comparing sequence features within and between species has become a part of most biological inquires [12]. Currently, 183 fungi genomes have been sequenced, either completely or are in the process of sequencing, and 40 human pathogenic fungi genomes have been sequenced. (Data collected on 09/07/2010 in the following databases: Fungal Genomes, TIGR, Sanger, Broad Institute and NCBI). Seven of the human pathogens are of great importance in systemic mycosis: Candida albicans, Aspergillus fumigatus, Blastomyces dermatitidis, Coccidioides immitis, Cryptococcus neoformans, Paracoccidioides brasiliensis and Histoplasma capsulatum, which are strong candidates for post-genomic studies.

Comparative genomics strategy is a useful tool in identifying potential new drug targets, such as putative essential genes and/or those affecting the cell viability that are conserved in pathogenic organisms [1316]. By this methodology, ten genes conserved in three bacteria species (Staphylococcus aureus, Mycobacterium tuberculosis and Escherichia coli 0157: H7) were selected as candidates for an antibacterial drug [14]. Since the publication of the nematode Brugia malayi complete genome, Kumar and colleagues [15] conducted a comparison analysis between the genomes of B. malayi and Caenorhabditis elegans and were able to identify 7,435 orthologs genes, from which 589 were identified as essential, as well as absent in the human genome, resulting in a list of candidate target genes for new drug development. Recently, Caffrey and colleagues [16] identified new drug targets in the metazoan pathogen Schistosoma mansoni, the causative agent of Schistosomiasis. The authors identified 35 orthologs essential genes and potential drug targets against this human pathogen.

Here we identified potential drug targets applied to human fungal pathogens using comparative genomics strategy. Ten genes were present in all pathogenic fungi analyzed and absent in the human genome. Among them, four genes (trr1, rim8, kre2 and erg6) were selected for future research and new drug development. Two of those genes codify for proteins (TRR1 and KRE2) that showed significant identity when compared to templates already deposited in the databank PDB (Protein Database Bank), which were used to perform homology modeling of both enzymes. These results will be used to virtually screen combinatorial libraries, offering new perspectives on technological development and innovation of antifungal agents against human pathogens.

Results and Discussion

Drug target selection

Direct demonstration of A. fumigatus and C. albicans gene essentiality was achieved using conditional promoter replacement (CPR) [17] and gene replacement and conditional expression (GRACE) strategies [18], respectively. Therefore, the initial ensemble of genes, experimentally described as essential in C. albicans and/or A. fumigatus were used to identify 55 orthologs. In addition, two non-essential genes (kre2 and erg6), but which are important to cell viability within the host [19, 20], were added to the list of possible drug targets. The alignments of those 57 sequences against the genome of the 8 pathogenic fungi P. lutzii, P. brasiliensis isolates (Pb18 e Pb3), A. fumigatus, B. dermatitidis, C. albicans, C. immitis, C. neoformans, H. capsulatum confirmed the presence of all the genes (Additional file 1). As a result, ten conserved genes were selected as drug targets because they were present in all species analyzed and were also absent in the human genome, as shown in Table 1.
Table 1

Potential target genes selected for new antifungal drug development


Biological process


PDB template



PDB sequence identidy (%)


Cell redox homeostasis



Saccharomyces cerevisiae





Arabidopsis thaliana




Cellular metabolism

Golgi and membrane






Ribosome biogenesis



Methanocaldococcus jannaschii




Cell wall biogenesis/degradation







Protein transport

Mitochondrion membrane


Homo sapiens




Cell wall biogenesis/degradation

Golgi apparatus Membrane


Pyrococcus furiosus




Cell wall organization/biogenesis



Neisseria meningitidis




Protein mannosilation

Golgi membrane


Saccharomyces cerevisiae




Ergosterol biosynthesis

Endoplasmatic reticulum membrane


Lechevalieria aerocolonigenes




pH-response regulator



Bacteroides fragilis



* Structure absent in PDB (

Six criteria were used to select the potential targets: 1) be essential or relevant for fungi survival; 2) be present in all analyzed pathogens, therefore allowing a broad spectrum of drug action; 3) be absent in the human genome, therefore avoiding unwanted side effects; 4) be preferentially an enzyme and have the potential for assayability; 5) not be auxotrophic, thereby avoiding host provision of the necessary substrate for the blocked pathway; and 6) have a cellular localization potentially accessible to the drug activity. Applying these criteria, four potential drug targets were identified: trr1, rim8, kre2 and erg6 genes. Only trr1 and rim8 are essential genes, but kre2 and erg6 are involved in cell viability and survival within the host. In addition, those genes were also identified as potential drug targets in P. lutzii isolate Pb01 transcriptome, as described by Felipe and colleagues [21].

The trr1 is an essential gene that encodes for the cytoplasmatic enzyme thioredoxin reductase [22]. This protein plays a critical role in maintaining the cell redox status [22] and is part of the complex so-called thioredoxin system, which contains thioredoxin (Trx), thioredoxin reductase (Trr) and NADPH, protecting cells against oxidative stress [23]. Thioredoxin reductase is necessary for the viability of C. neoformans[24] and is essential for erythrocytic stages in Plasmodium falciparum[25]; it also appears to be essential for growth in S. aureus[26]. S. cerevisiae strain deleted for trr1 gene is hypersensitive to hydrogen peroxide and high temperatures [27, 28].

The rim8 is also an essential gene that encodes for a protein involved in the proteolytic activation of a transcriptional factor in response to alkaline pH and is located near the plasma membrane [29]. RIM8 (for yeasts) or PalF (for filamentous fungi) protein binds strongly to the C-terminal cytoplasmic tail of the seven transmembrane domains, the putative pH sensor PalH. Alignment of protein sequences suggests structural similarity of RIM8 to mammalian arrestins, but the sequence similarity was restricted to short stretches of amino acid sequences, mostly corresponding to β-strands in arrestin crystal structures [30]. The RIM8 protein performs an essential step in the signaling pathway activating RIM101, which, in turn, regulates alkaline pH-response. This pathway is also involved in the activation of the yeast-to-hyphal transition required for host-pathogen interaction [31].

The kre2 gene encodes for the enzyme α-1,2-mannosyltransferase that is located in the Golgi complex. It has a short amino-terminal cytoplasmic domain, a hydrophobic membrane-spanning domain and a large carboxy-terminal catalytic domain [32]. This enzyme is responsible for the addition of the α-1,2-linked mannose residues to O-linked carbohydrates and is also involved in N-linked glycosylation [3336]. Cell wall-associated proteins are commonly glycosylated and defects in this process may result in protein misfolding, instability, and/or reduced enzymatic activity [36]. Absence of MNT1p in S. cerevisiae resulted in the synthesis of truncated O-linked oligosaccharides and this interfered with the functioning and/or synthesis of cell wall compounds [33, 34]. Mutants of C. albicans that lack CaMNT1 and CaMNT2 have truncated O-mannan, marked reduction in adherence and attenuated virulence [34]. Although CaMNT1p is not essential for viability, MNT1p-mediated O-glycosylation of proteins of C. albicans is essential for normal host-fungus interactions [37].

The erg6 gene encodes for the enzyme Δ-(24)-Sterol C-methyltransferase that is located in the endoplasmic reticulum. It shows a transmembrane portion and an active site positioned toward the cytoplasm [38, 39]. This enzyme catalyzes the attachment of a methyl group acting in a bifurcation point of the ergosterol/cholesterol biosynthesis pathway [40]. In S. cerevisiae, erg6 mutants showed alteration in membrane fluidity and permeability [41, 42]. In C. albicans, mutants that do not synthesize Δ-(24)-Sterol C-methyltransferase showed an increase in the plasma membrane permeability, resulting in cells with severely compromised phenotypes [20]. erg6 mutants, in Candida lusitaniae, showed a severe growth defect and decreased ergosterol content [43].

Conserved domains in protein sequences and phylogenetic analysis

A multiple protein sequence alignment showed the presence of conserved domains mainly in the catalytic site of the four selected candidates (Additional files 2, 3, 4, 5). The catalytic site of the protein TRR1 contains the four-amino acid-residue sequence Cys-Ala-Thr-Cys [44, 22, 45], and these two highly conserved cysteine residues (Cys142 and Cys145 in C. albicans) are essential for its redox activity (Additional file 2). RIM8 protein alignments showed that in the C-terminal domain, the residue Ile-331 of A. nidulans, involved in PalF-PalH receptor binding, was conserved in all the fungi sequences (it is located in position Ile-320 in P. brasiliensis). The amino acid residue Ser-86 of A. nidulans, present in the N-terminal domain and responsible for PalF-PalH interaction and pH signaling, was replaced by the conserved Cys-75 in P. brasiliensis, B. dermatitidis, H. capsulatum, Cys-76 in C. immitis and Cys-77 in A. fumigatus (Additional file 3).

The catalytic site of KRE2 proteins contains the conserved amino acid residues His312, His377, Asp350 and Glu318 in C. albicans. If those residues are individually replaced, in C. albicans, the enzyme activities are fully abolished [46, 47]. Our analysis showed highly conserved catalytic domains of all the sequences of the analyzed proteins for all the pathogenic fungi. The domain YNLCHFWSNFEI, previously described as important to the catalysis mechanism, was also conserved in all fungi analyzed (Additional file 4).

The ERG6 protein showed four conserved regions in several sterol methyltransferase (SMT) proteins, including Regions II, III and IV, generally present in AdoMet-dependent enzymes and, Region I, observed in all SMT enzymes [48]. Region I, a highly conserved region rich in aromatic amino acids, contains a signature motif YEXGWG [49]. The mutation of the amino acid residues situated in Region I altered the catalytic behavior of the fungal SMT [5052]. In addition, specific-site mutation in Region II and Region III of ERG6 protein showed that certain residues (Cys128, Gly129, Pro133 and Ala193 in S. cerevisiae) were important to C-methylation activity [52]. All important amino acid residues for ERG6 protein activity were conserved in all fungi genomes analyzed (Additional file 5).

The alignments of protein sequences were also used in phylogenetic studies performed by Bayesian analysis to construct phylogenetic trees relating TRR1, RIM8, KRE2 and ERG6 orthologs. The phylogenetic trees showed the evolutionary relationships between the different species used in this work and separated them in different groups (Figure 1). P. brasiliensis, B. dermatitidis, H. capsulatum, A. fumigatus and C. immitis were clustered apart from C. albicans and C. neoformans. The posterior probability values were added to the phylogenetic branches and received values near 1, showing the consistency and reliability of these branches. In the four phylogenetic trees, the P. brasiliensis isolate Pb01 was separated from the other isolates (Pb3 and Pb18). These findings are in agreement with Teixeira et al. 2009 [53], in which 13 single-locus topologies showed that the genus Paracoccidioides contains two highly divergent groups. As proposed by Teixeira and colleagues [53], these results reinforce the existence of two species for Paracoccidioides genus: P. brasiliensis (Pb18 and Pb3) and P. lutzii (Pb01).
Figure 1
Figure 1

Phylogenetic analysis between human pathogenic fungi performed by Bayesian analysis. Phylogenetic trees generated from Bayesian analysis of the genes trr1 (a), rim8 (b), kre2 (c) and erg6 (d). The length of the vertical lines linking one protein is proportional to the estimated distance between their sequences. The posterior probability values were added to the phylogenetic branches. Af: Aspergillus fumigatus, Bd: Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis, Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum, Pl: Paracoccidioides lutzii, Pb3: P. brasiliensis isolate 3, Pb18: P. brasiliensis isolate 18.

Homology modeling of TRR1 and KRE2

In the absence of experimentally solved structures, computational methods were used to predict 3D protein models and provide information regarding protein functions and structures [54]. Homology modeling is efficient in new drug design, from the biological target conception through new drug discovery [55]. Of the four selected potential targets obtained from our comparative genomic analyses, only TRR1 and KRE2 showed a reasonable sequence identity to the templates found in PDB (Table 1). Consequently, we performed the homology modeling only for these two proteins.

According to the BLAST search performed on the entire PDB database, the thioredoxin reductase (TRR1) of P. brasiliensis showed good sequence identity with two templates, specifically 3ITJ (PDB ID) of S. cerevisiae (65% sequence identity) and 1VDC (PDB ID) of Arabidopsis thaliana (57% sequence identity). In the case of α-1,2-mannosyltransferase (KRE2) of P. brasiliensis, only the PDB template 1S4N (PDB ID) of S. cerevisiae showed a reasonable sequence identity (50%). Starting from the BLAST alignment between P. brasiliensis TRR1 and KRE2 proteins with the PDB templates as found above, we manually modified them in order to preserve the secondary structures and the correspondence between cysteine residues (Additional file 6a and 6b).

In these alignments between the target sequences and template structures, a fragment of the C-terminus region of TRR1 (Glu325-Leu358) and of the N-terminus region of KRE2 (Met1-Phe70) did not align. Therefore, a BLAST search with the fragment sequences was performed to verify if these regions had similarity with proteins deposited in the PDB. No confirmation was found, so these fragment terminus regions of TRR1 and KRE2 were removed from the models. This was legitimate, since these fragments are not involved in the active site of the proteins and should not interfere with the virtual screening that we intend to perform using these models.

The refinement of the homology models was obtained through molecular mechanics optimization; the stable structures of TRR1 and KRE2 are displayed in Figure 2. Figure 2a shows that the enzyme TRR1 has 9 helices and 17 sheets. Figure 2b shows that the enzyme KRE2 has 18 helices and 11 sheets.
Figure 2
Figure 2

The predicted tridimensional structure of TRR1 and KRE2 proteins obtained by homology modeling. The structures of TRR1 (a) and KRE2 (b) proteins. The α-helix is represented by the color red, the β-sheet is represented by yellow and loops are represented by green. (a - left panel) The KRE2 active site presents the conserved residues His292, His357, Asp330 and Glu298. (Mutation of these residues abolished the protein activity in C. albicans.) Additional residues found in the KRE2 active site include Glu216, which interacts with the metal ion Mn2+ and creates the reactive nucleophylic center for the glycosyltransferase reaction, and Tyr189, which coordinates the donor and acceptor binding that allows the transfer of the mannose to the growing oligosaccharide. (b - right panel) The TRR1 protein is composed of two domains that comprise the binding sites of NADPH and FAD. The NADPH binding domain contains the active Cys145 and Cys148 residues. Other important residues of the TRR1 active site are Ala151, Val152, Pro153 and Ile154 that form a hydrophobic region in the NADPH binding domain.

The TRR1 monomeric protein of S. cerevisiae is composed of two domains that form the binding sites of NADPH and FAD similar to plants. The FAD molecule is bound to the S. cerevisiae TRR1 protein and is stabilized by interactions with the residues Pro13, Glu33, Gln45, Asn54, Gln136, Asp288 and Gln296. The NADPH binding domain contains active cysteine residues and is linked to the FAD domain by a short β-sheet [56, 57]. Figure 2a shows the two domains in the P. brasiliensis TRR1 model.

In KRE2 protein, the catalytic mechanism of the active site involves nucleophylic substitutions mediated by acidic amino acid residues and an essential Mn2+ cofactor. Heterologous expression of site-specific mutants of C. albicans MNT1 protein in Pichia pastoris confirmed the nature of a nucleophilic reaction center, where the two conserved histidines (His292 and His357 in P. brasiliensis) that coordinated the metal ion cofactor Mn2+ and created the reactive nucleophylic center required the nonprocessing, GDP-mannose-dependent, retaining glycosyltransferase reaction [46]. However, Lobsanov and colleagues [47] examined the structure and catalysis mechanism of S. cerevisiae KRE2 enzyme (1S4N template) by crystallography and proposed a novel mechanism for this interaction, and the precise function for the conserved amino acids was determined by site-direct mutagenesis by Thomson and colleagues [46]. The proposed mechanism of retaining glycosyltransferases such as CaMNT1p involves a two-step displacement. The first step involves attack on the sugar anomeric center by one of the carboxylates, and then a second carboxylate acts as the active site nucleophilic to displace the GDP from the sugar nucleotide, leading to formation of a glycosyl-enzyme intermediate. The metal ion Mn2+ is coordinated by a direct interaction of the residue glutamate (Glu216 in KRE2 protein of P. brasiliensis) as shown in Figure 2b, right panel. Transfer of the mannose to the growing oligosaccharide is completed by displacement of the enzyme from the intermediate by the hydroxyl group of the acceptor [46]; in C. albicans KRE2 protein, tyrosine (Tyr209) coordinates the donor and acceptor binding from the N-terminal domain and plays a role in the catalysis [47].


We reported a comparative genomic strategy to provide a list of potential antifungal drug targets for the human pathogenic fungi P. brasiliensis, P. lutzii, A. fumigatus, B. dermatitidis, C. albicans, C. immitis, C. neoformans and H. capsulatum. The preferred profile for fungal targets was proteins conserved among these fungi, but absent in the human genome, aiming to minimize the potential toxic side effects exerted by pharmacological inhibition of the cellular targets. In general, the potential drug targets were selected following the criteria of essentiality, presence in all human pathogenic fungi considered here, absence in humans, be preferentially an enzyme, not be auxotrophic and have accessible cell localization.

In silico and manual mining provided four genes as potential drug targets: trr1 that encodes for thioredoxin reductase, rim8 that encodes for a protein involved in the proteolytic activation of a transcriptional factor in response to alkaline pH, kre2 that encodes for α-1,2-mannosyltransferase and erg6 that encodes for Δ-(24)-Sterol C-methyltransferase. The increase in structural databases allows the satisfactory prediction of structures by theoretical methods, with advantages over more costly experimental methods. We performed the homology modeling for the potential targets that were identified to have a known 3D structure and that showed good sequence identity to the templates found in PDB, TRR1 and KRE2. In the absence of structures solved experimentally, the available homology modeling tools were extremely useful for the structural prediction of the TRR1 and KRE2 proteins. From this first step of post-genomic analysis, we obtained relevant information for future technological development. Moreover, these results are being used to virtually screen chemical libraries, which are under progress, generating new perspectives on technological development and innovation of antifungal agents to these human pathogens.


Comparative analysis of human pathogenic fungi genomes and drug target selection

The identification of potential drug targets was based on 55 genes experimentally confirmed as essential for Candida albicans[17] or Aspergillus fumigatus[18]. In these cases, the genes were experimentally confirmed as essential and represent a large spectrum of biological functions, such as cellular metabolism, cell wall organization and biogenesis, ergosterol biosynthesis, ribosomal biogenesis and post-translational modification of protein [17, 18]. Other 2 genes (kre2 and erg6) were added to the initial screening since they were described as potential drug targets [21].

The 57 gene sequences of were retrieved from the GenBank databases ( and were used to screen the P. brasiliensis Pb01 transcriptome database ( using blastn. The sequences of Paracoccidioides lutzii isolate Pb01 were not applied as a filter since all 57 genes were present and expressed in its genome/transcriptome. Subsequently, the presence of these genes in the 2 isolates of P. brasiliensis (Pb3 and Pb18) was confirmed. Using the isolate Pb01 sequence, released by Broad Institute (, the orthologs search in other pathogenic fungi (A. fumigatus Af293, B. dermatitidis ER3, C. albicans WO1, C. immitis H538.4, C. neoformans serotype B, H. capsulatum NAm1) and human genome was completed using blastx because we have focused in the development of a new antifungal not only for the Paracoccidioides species but for all medically important fungi. The cut-off established for determining the presence of an ortholog was a maximum E-value of 0.00001 (1e-5). A manual curation was performed to select the potential drug targets following the criteria of essentiality, be present in pathogenic fungi, be absent in humans, be preferentially an enzyme, not be auxotrophic and have accessible cell localization.

Multiple alignments of the orthologs genes and phylogenetic analysis

Sequences were aligned by the ClustalW using dynamic programming and hierarchical methods [58] available in the BioEdit software [59]. The program identified conserved regions in the protein sequences between orthologs target genes by multiple sequence alignments.

The sequences were also used for phylogenetic analysis by Bayesian inference using Mr. Bayes software, version 3.1.2 [60]. Detected gaps in sequence alignments were considered missing data and coded in terms of presence or absence. The amino acid substitution model selected was JTT [61]. The Markov Chain Monte Carlo (MCMC) was initiated from a random tree and processed for 1000000 generations; sample trees were retrieved every 1000 generations. Log-likelihood values were plotted against the generation number, and the first 25% of samples were discarded ("burn-in"). The remaining samples were used to determine the distribution of posterior probability values. Phylogenetic trees were produced with the help of the Treeview and Figtree 1.0 software.

Protein structure prediction

There is no crystallographic structure presently available for TRR1 and KRE2 of P. brasiliensis and also for the other pathogenic fungi. Therefore, the 3D structures of TRR1 and KRE2 of P. brasiliensis were constructed by homology modeling based on known structures with high percentage of identity in amino acid sequences. We have initially modeled P. brasiliensis proteins but it will be similar for the other pathogenic fungi since the sequences of the proteins are highly conserved. The known template structures were searched in the PDB. There were two templates for TRR1 protein: 3ITJ (PDB ID) of S. cerevisiae and 1VDC (PDB ID) of A. thaliana. There was one template for KRE2 protein: 1S4N (PDB ID) of S. cerevisiae. The templates structures for ERG6 and RIM8 showed low sequence identity, then not allowed the construction of 3D structures for these proteins by molecular modeling. The amino acid residue sequences of TRR1 and KRE2 were compared with the primary sequences of the structures deposited in the PDB using the BLAST program. The homologous sequences allowed the construction of a 3D model of TRR1 and KRE2 using the homology module of the Insight II software package (Biosym/MSI, San Diego, Accelrys Inc. 2001). Briefly, the target sequences were aligned with the template structures, and coordinates from the templates were transferred to the targets TRR1 and KRE2. For model optimization, the backbone atoms of the structures were initially frozen and only the side chains were allowed to move for a selective minimization by conjugate gradient method. A second selective minimization, also by conjugate gradient method, was performed with only atoms of the complementary determining region (CDR) loops moving. The last minimization was performed by Steepest-descent method with all atoms of the structure relaxed, resulting in whole, refined 3D structures. The molecular visualization was performed by PyMOL open-source software version 0.99rc6 (Delano Scientific LLC, 2006).



The authors gratefully acknowledge the Brazilian Agencies CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) and FAP-DF (Fundação de Apoio a Pesquisa do Distrito Federal) for financial support.

Authors’ Affiliations

Department of Cellular Biology, University of Brasília, Brasília, Brazil
Embrapa - Genetic Resources and Biotechnology, Brasília, Brazil
Lorrain Laboratory of Computing Research and its Applications, University Henri Poincaré-Nancy I, Nancy, France


  1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001, 33: 641-647. 10.1086/322606.View ArticlePubMedGoogle Scholar
  2. Alvez F, Figueras C, Roselló E: Emerging invasive fungal infections. An Pediatr (Barc). 2010, 73: 52.e1-52.e6. 10.1016/j.anpedi.2010.04.009.View ArticleGoogle Scholar
  3. Sable CA, Strohmaier KM, Chodakewitz JA: Advances in antifungal therapy. Annu Rev Med. 2008, 59: 361-379. 10.1146/ ArticlePubMedGoogle Scholar
  4. Chapman SW, Sullivan DC, Cleary JD: In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc. 2008, 119: 197-215.PubMedPubMed CentralGoogle Scholar
  5. Moen MD, Lyseng-Williamson KA, Scott LJ: Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009, 69: 361-92. 10.2165/00003495-200969030-00010.View ArticlePubMedGoogle Scholar
  6. Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009, 48: 1441-58. 10.1086/598327.View ArticlePubMedGoogle Scholar
  7. Fera MT, La Camera E, De Sarro A: New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert review of anti-infective therapy. 2009, 7: 981-998. 10.1586/eri.09.67.View ArticlePubMedGoogle Scholar
  8. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998, 27: 603-18. 10.1086/514704.View ArticlePubMedGoogle Scholar
  9. Olson JA, Adler-Moore JP, Jensen GM, Schwartz J, Dignani MC, Proffitt RT: Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother. 2008, 52: 259-268. 10.1128/AAC.00870-07.View ArticlePubMedGoogle Scholar
  10. Amaral AC, Bocca AL, Ribeiro AM, Nunes J, Peixoto DL, Simioni AR, Primo FL, Lacava ZG, Bentes R, Titze-de-Almeida R, Tedesco AC, Morais PC, Felipe MS: Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J Antimicrob Chemother. 2009, 63: 526-533. 10.1093/jac/dkn539.View ArticlePubMedGoogle Scholar
  11. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010, 9: 203-14.PubMedGoogle Scholar
  12. Jung K, Park J, Choi J, Park B, Kim S, Ahn K, Choi J, Choi D, Kang S, Lee YH: SNUGB: a versatile genome browser supporting comparative and functional fungal genomics. BMC Genomics. 2008, 9: 586-10.1186/1471-2164-9-586.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Janaki C, Joshi RR: Accelerating Comparative Genomics Using Parallel Computing. In Silico Biology. 2003, 3: 429-440.PubMedGoogle Scholar
  14. White TA, Kell DB: Comparative genomic assessment of novel broad-spectrum targets for antibacterial drugs. Comp Funct Genomics. 2004, 5: 304-327. 10.1002/cfg.411.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Kumar S, Chaudhary K, Foster JM, Novelli JF, Zhang Y, Wang S, Spiro D, Ghedin E, Carlow CKS: Mining Predicted Essential Genes of Brugia malayi for Nematode Drug Targets. PLoS ONE. 2007, 2: e1189-10.1371/journal.pone.0001189.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Caffrey CR, Rohwer A, Oellien F, Marhöfer RJ, Braschi S, Oliveira G, McKerrow JH, Selzer PM: A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One. 2009, 4: e4413-10.1371/journal.pone.0004413.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Roemer T, Jiang B, Davison J, Ketela T, Veillette K, Breton A, Tandia F, Linteau A, Sillaots S, Marta C, Martel N, Veronneau S, Lemieux S, Kauffman S, Becker J, Boone C, Bussey H: Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Molecular Microbiology. 2003, 50: 167-181. 10.1046/j.1365-2958.2003.03697.x.View ArticlePubMedGoogle Scholar
  18. Hu W, Sillaots S, Lemieux S, Davison J, Kauffman S, Breton A, Linteau1 A, Xin C, Bowman J, Becker J, Jiang B, Roemer T: Essential gene identification and drug target prioritization in Aspergillus fumigates. PLoS pathogens. 2007, 3: e24-10.1371/journal.ppat.0030024.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Buurman ET, Westwater C, Hube B, Brown AJ, Odds FC, Gow NA: Molecular analysis of CaMnt1p, a mannosyltransferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci USA. 1998, 95: 7670-5. 10.1073/pnas.95.13.7670.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Jensen-Pergakes KL, Kennedy MA, Lees ND, Barbuch R, Koegel C, Bard M: Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants. Antimicrobial Agents and Chemotherapy. 1998, 42: 1160-1167.PubMedPubMed CentralGoogle Scholar
  21. Felipe MS, Andrade RV, Arraes FB, Nicola AM, Maranhão AQ, Torres FA, Silva-Pereira I, Poças-Fonseca MJ, Campos EG, Moraes LM, Andrade PA, Tavares AH, Silva SS, Kyaw CM, Souza DP, Pereira M, Jesuíno RS, Andrade EV, Parente JA, Oliveira GS, Barbosa MS, Martins NF, Fachin AL, Cardoso RS, Passos GA, Almeida NF, Walter ME, Soares CM, Carvalho MJ, Brígido MM, PbGenome Network: Transcriptional profiles of the human pathogenic fungus Paracoccidioides brasiliensis in mycelium and yeast cells. J Biol Chem. 2005, 280: 24706-24714. 10.1074/jbc.M500625200.View ArticlePubMedGoogle Scholar
  22. Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, Veine DM, Becker K, Schirmer RH: Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem. 2000, 267: 6110-6117. 10.1046/j.1432-1327.2000.01702.x.View ArticlePubMedGoogle Scholar
  23. Arnér ES, Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000, 267: 6102-6109. 10.1046/j.1432-1327.2000.01701.x.View ArticlePubMedGoogle Scholar
  24. Missall TA, Lodge JK: Thioredoxin reductase is essential for viability in the fungal pathogen Cryptococcus neoformans. Eukaryot Cell. 2005, 4: 487-9. 10.1128/EC.4.2.487-489.2005.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Krnajski Z, Gilberger TW, Walter RD, Cowman AF, Muller S: Thioredoxin reductase is essential for the survival of Plasmodium falciparum erythrocytic stages. J Biol Chem. 2002, 277: 25970-25975. 10.1074/jbc.M203539200.View ArticlePubMedGoogle Scholar
  26. Uziel O, Borovok I, Schreiber R, Cohen G, Aharonowitz Y: Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J Bacteriol. 2004, 186: 326-334. 10.1128/JB.186.2.326-334.2004.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Machado AK, Morgan BA, Merrill GF: Thioredoxin reductase-dependent inhibition of MCB cell cycle box activity in Saccharomyces cerevisiae. J Biol Chem. 1997, 272: 17045-17054. 10.1074/jbc.272.27.17045.View ArticlePubMedGoogle Scholar
  28. Pearson GD, Merrill GF: Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem. 1998, 273: 5431-5434. 10.1074/jbc.273.10.5431.View ArticlePubMedGoogle Scholar
  29. Peñalva MA, Arst HN: Regulation of gene expression by ambient pH in filamentous fungi and yeasts. Microbiology and Molecular Biology Reviews. 2002, 66: 426-446. 10.1128/MMBR.66.3.426-446.2002.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Herranz S, Rodríguez JM, Bussink HJ, Sánchez-Ferrero JC, Arst HN, Peñalva MA, Vincent O: Arrestin-related proteins mediate pH signaling in fungi. Proc Natl Acad Sci USA. 2005, 102: 12141-12146. 10.1073/pnas.0504776102.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Davis D, Edwards JE, Mitchell AP, Ibrahim AS: Candida albicans RIM101 pH response pathway is required for host-pathogen interactions. Infect Immun. 2000, 68: 5953-5959. 10.1128/IAI.68.10.5953-5959.2000.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Lussier M, Sdicu AM, Ketela T, Bussey H: Localization and targeting of the Saccharomyces cerevisiae Kre2p/Mnt1p alpha 1,2-mannosyltransferase to a medial-Golgi compartment. J Cell Biol. 1995, 131: 913-927. 10.1083/jcb.131.4.913.View ArticlePubMedGoogle Scholar
  33. Häusler A, Ballou L, Ballou CE, Robbins PW: Yeast glycoprotein biosynthesis: MNT1 encodes an alpha-1,2-mannosyltransferase involved in O-glycosylation. Proc Natl Acad Sci USA. 1992, 89: 6846-6850. 10.1073/pnas.89.15.6846.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Hill K, Boone C, Goebl M, Puccia R, Sdicu AM, Bussey H: Yeast KRE2 Defines a New Gene Family Encoding Probable Secretory Proteins, and Is Required for the Correct N-Glycosylation of Proteins. Genetics. 1992, 130: 273-283.PubMedPubMed CentralGoogle Scholar
  35. Lussier M, Sdicu AM, Bussereau F, Jacquet M, Bussey H: The Ktr1p, Ktr3p, and Kre2p/Mnt1p mannosyltransferases participate in the elaboration of yeast O- and N-linked carbohydrate chains. The Journal of Biological Chemistry. 1997, 272: 15527-15531. 10.1074/jbc.272.24.15527.View ArticlePubMedGoogle Scholar
  36. Wagener J, Echtenacher B, Rohde M, Kotz A, Krappmann S, Heesemann J, Ebel F: The putative alpha-1,2-mannosyltransferase AfMnt1 of the opportunistic fungal pathogen Aspergillus fumigatus is required for cell wall stability and full virulence. Eukaryot Cell. 2008, 7: 1661-1673. 10.1128/EC.00221-08.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Munro CA, Bates S, Buurman ET, Hughes HB, Maccallum DM, Bertram G, Atrih A, Ferguson MA, Bain JM, Brand A, Hamilton S, Westwater C, Thomson LM, Brown AJ, Odds FC, Gow NA: Mnt1p and Mnt2p of Candida albicans are partially redundant alpha-1,2-mannosyltransferases that participate in O-linked mannosylation and are required for adhesion and virulence. J Biol Chem. 2005, 280: 1051-1060. 10.1074/jbc.M411413200.View ArticlePubMedGoogle Scholar
  38. McCammon MT, Hartmann Ma, Bottema CD, Parks LW: Sterol methylation in Saccharomyces cerevisiae. Journal of bacteriology. 1984, 157: 475-483.PubMedPubMed CentralGoogle Scholar
  39. Natter K, Leitner P, Faschinger A, Wolinski H, McCraith S, Fields S, Kohlwein SD: The spatial organization of lipid synthesis in the yeast Saccharomyces cerevisiae derived from large scale green fluorescent protein tagging and high resolution microscopy. Mol Cell Proteomics. 2005, 4: 662-672. 10.1074/mcp.M400123-MCP200.View ArticlePubMedGoogle Scholar
  40. Nes WD, Janssen GG, Bergenstrahle A: Structural requirements for transformation of substrates by the (S)-adenosyl-L-methionine:delta 24(25)-sterol methyl transferase. J Biol Chem. 1991, 266: 15202-15212.PubMedGoogle Scholar
  41. Gaber RF, Copple DM, Kennedy BK, Vidal M, Bard M: The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol. Molecular and Cellular Biology. 1989, 9: 3447-3456.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Zweytick D, Leitner E, Kohlwein SD, Yu C, Rothblatt J, Daum G: Contribution of Are1p and Are2p to steryl ester synthesis in the yeast Saccharomyces cerevisiae. Eur J Biochem. 2000, 267: 1075-1082. 10.1046/j.1432-1327.2000.01103.x.View ArticlePubMedGoogle Scholar
  43. Young LY, Hull CM, Heitman J: Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother. 2003, 47: 2717-2724. 10.1128/AAC.47.9.2717-2724.2003.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Veine DM, Mulrooney SB, Wang PF, Williams CH: Formation and properties of mixed disulfides between thioredoxin reductase from Escherichia coli and thioredoxin: evidence that cysteine-138 functions to initiate dithiol-disulfide interchange and to accept the reducing equivalent from reduced flavin. Protein Sci. 1998, 7: 1441-50. 10.1002/pro.5560070621.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Zhang Z, Bao R, Zhang Y, Yu J, Zhou CZ, Chen Y: Crystal structure of Saccharomyces cerevisiae cytoplasmic thioredoxin reductase Trr1 reveals the structural basis for species-specific recognition of thioredoxin. Biochim Biophys Acta. 2009, 1794: 124-128.View ArticlePubMedGoogle Scholar
  46. Thomson LM, Bates S, Yamazaki S, Arisawa M, Aoki Y, Gow NA: Functional characterization of the Candida albicans MNT1 mannosyltransferase expressed heterologously in Pichia pastoris. J Biol Chem. 2000, 275: 18933-8. 10.1074/jbc.M909699199.View ArticlePubMedGoogle Scholar
  47. Lobsanov YD, Romero PA, Sleno B, Yu B, Yip P, Herscovics A, Howell PL: Structure of Kre2p/Mnt1p: a yeast alpha1,2-mannosyltransferase involved in mannoprotein biosynthesis. J Biol Chem. 2004, 279: 17921-17931. 10.1074/jbc.M312720200.View ArticlePubMedGoogle Scholar
  48. Nes WD, McCourt BS, Zhou W, Ma J, Marshall JA, Peek LA, Brennan M: Overexpression, purification, and stereochemical studies of the recombinant (S)-adenosyl-L-methionine: D24(25)- to D24(28)-sterol methyl transferase enzyme from Saccharomyces cerevisiae. Arch Biochem Biophys. 1998, 353: 297-311. 10.1006/abbi.1998.0665.View ArticlePubMedGoogle Scholar
  49. Nes WD, Marshall JA, Jia Z, Jaradat TT, Song Z, Jayasimha P: Active site mapping and substrate channeling in the sterol methyltransferase pathway. J Biol Chem. 2002, 277: 42549-56. 10.1074/jbc.M204223200.View ArticlePubMedGoogle Scholar
  50. Nes WD, McCourt BS, Marshall JA, Ma J, Dennis AL, Lopez M, Li H, He L: Site-directed mutagenesis of the sterol methyl transferase active site from Saccharomyces cerevisiae results in formation of novel 24-ethyl sterols. J Org Chem. 1999, 64: 1535-1542. 10.1021/jo9819943.View ArticlePubMedGoogle Scholar
  51. Nes WD: Enzyme redesign and interactions of substrate analogues with sterol methyltransferase to understand phytosterol diversity, reaction mechanism and the nature of the active site. Biochem Soc Trans. 2005, 33: 1189-1196. 10.1042/BST20051189.View ArticlePubMedGoogle Scholar
  52. Ganapathy K, Jones CW, Stephens CM, Vatsyayan R, Marshall JA, Nes WD: Molecular probing of the Saccharomyces cerevisiae sterol 24-C methyltransferase reveals multiple amino acid residues involved with C2-transfer activity. Biochim Biophys Acta. 2008, 1781: 344-351.View ArticlePubMedGoogle Scholar
  53. Teixeira MM, Theodoro RC, de Carvalho MJ, Fernandes L, Paes HC, Hahn RC, Mendoza L, Bagagli E, San-Blas G, Felipe MS: Phylogenetic analysis reveals a high level of speciation in the Paracoccidioides genus. Mol Phylogenet Evol. 2009, 52: 273-83. 10.1016/j.ympev.2009.04.005.View ArticlePubMedGoogle Scholar
  54. Cavasotto CN, Phatak SS: Homology modeling in drug discovery: current trends and applications. Drug Discov Today. 2009, 14: 676-683. 10.1016/j.drudis.2009.04.006.View ArticlePubMedGoogle Scholar
  55. Marshall GR: Introduction to cheminformatics in drug discovery - A personal view. Chemioinformatics in drug discovery. Edited by: Tudor I. 2004, Oprea, Weinhein: WILEY-VHC, 23: ISBN: 3-527-30753-2Google Scholar
  56. Dai S, Saarinen M, Ramaswamy S, Meyer Y, Jacquot JP, Eklund H: Crystal Structure of Arabidopsis thaliana NADPH Dependent Thioredoxin Reductase at 2.5 Å Resolution. J Mol Biol. 1996, 264: 1044-1057. 10.1006/jmbi.1996.0695.View ArticlePubMedGoogle Scholar
  57. Oliveira MA, Discola KF, Alves SV, Medrano FJ, Guimarães BG, Netto LES: Insights into the specificity of thioredoxin reductase-thioredoxin interactions. A structural and functional investigation of the yeast thioredoxin system. Biochemistry. 2010, 49: 3317-3326. 10.1021/bi901962p.View ArticlePubMedGoogle Scholar
  58. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22: 4673-80. 10.1093/nar/22.22.4673.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999, 41: 95-98.Google Scholar
  60. Ronquist F, Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics. 2003, 19: 1572-4. 10.1093/bioinformatics/btg180.View ArticlePubMedGoogle Scholar
  61. Jones DT, Taylor WR, Thornton JM: The Rapid Generation of Mutation Data Matrices from Protein Sequences. Comput Applic Biosci. 1992, 8: 275-282.Google Scholar


© Abadio et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.